Kymera appoints Terence Rooney as CMO; Jared Gollob retires after 8 years

Filed July 27, 2026 · Period ending July 27, 2026 · ~1 min read

Key Changes

• high

  Terence Rooney, MD, appointed Chief Medical Officer effective July 27, 2026, bringing extensive immunology drug development experience from J&J, Eli Lilly, and Roche, including work on approved medicines OLUMIANT, STELARA, and TREMFYA.

  Item 5.02 — Departure of Directors or Certain Officers; Election of Directors; Compensation verify on EDGAR →
• medium

  Jared Gollob, MD, retiring as CMO for personal reasons after eight years; will remain as advisor through December 31, 2026. Departure not due to any disagreement with company practices or policies.

  Item 5.02 — Departure of Directors or Certain Officers; Election of Directors; Compensation verify on EDGAR →
• medium

  Dr. Rooney will lead Kymera's global clinical development strategy and advancement of its oral immunology portfolio across multiple immuno-inflammatory diseases.

  Exhibit 99.1 view on EDGAR →